Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385841304> ?p ?o ?g. }
- W4385841304 endingPage "101133" @default.
- W4385841304 startingPage "101133" @default.
- W4385841304 abstract "New York esophageal squamous cell carcinoma-1 (NY-ESO-1)-specific T cell receptor (TCR) T cell therapy is effective in tumors with NY-ESO-1 expression, but a safe and effective TCR-T cell therapeutic protocol remains to be improved. Here, we report a phase 1 investigational new drug clinical trial with TCR affinity-enhanced specific T cell therapy (TAEST16001) for targeting NY-ESO-1. Enrolled patients receive TAEST16001 cell infusion after dose-reduced lymphodepletion with cyclophosphamide (15 mg/kg/day × 3 days) combined with fludarabine (20 mg/m2/day × 3 days), and the TCR-T cells are maintained with low doses of interleukin-2 injection post-adoptive transfer. Analysis of 12 patients treated with the regimen demonstrates no treatment-related serious adverse events. The overall response rate is 41.7%. The median progression-free survival is 7.2 months, and the median duration of response is 13.1 months. The protocol of TAEST16001 cells delivers a safe and highly effective treatment for patients with advanced soft tissue sarcoma (ClinicalTrials.gov: NCT04318964)." @default.
- W4385841304 created "2023-08-16" @default.
- W4385841304 creator A5006311071 @default.
- W4385841304 creator A5007198288 @default.
- W4385841304 creator A5021202757 @default.
- W4385841304 creator A5028159863 @default.
- W4385841304 creator A5029720669 @default.
- W4385841304 creator A5030829302 @default.
- W4385841304 creator A5030976623 @default.
- W4385841304 creator A5042807080 @default.
- W4385841304 creator A5049875048 @default.
- W4385841304 creator A5050096190 @default.
- W4385841304 creator A5050803462 @default.
- W4385841304 creator A5055035965 @default.
- W4385841304 creator A5055618825 @default.
- W4385841304 creator A5059368310 @default.
- W4385841304 creator A5064842058 @default.
- W4385841304 creator A5067835123 @default.
- W4385841304 creator A5068806771 @default.
- W4385841304 creator A5076676274 @default.
- W4385841304 creator A5078634382 @default.
- W4385841304 creator A5083925626 @default.
- W4385841304 creator A5088393463 @default.
- W4385841304 date "2023-08-01" @default.
- W4385841304 modified "2023-10-14" @default.
- W4385841304 title "Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma" @default.
- W4385841304 cites W1541816872 @default.
- W4385841304 cites W1983143892 @default.
- W4385841304 cites W1986592841 @default.
- W4385841304 cites W1999662775 @default.
- W4385841304 cites W2009253992 @default.
- W4385841304 cites W2010678553 @default.
- W4385841304 cites W2020312840 @default.
- W4385841304 cites W2060665573 @default.
- W4385841304 cites W2106582884 @default.
- W4385841304 cites W2141262236 @default.
- W4385841304 cites W2153712501 @default.
- W4385841304 cites W2165119413 @default.
- W4385841304 cites W2520576659 @default.
- W4385841304 cites W2560593922 @default.
- W4385841304 cites W2587048937 @default.
- W4385841304 cites W2610371878 @default.
- W4385841304 cites W2762797139 @default.
- W4385841304 cites W2783070348 @default.
- W4385841304 cites W2783897381 @default.
- W4385841304 cites W2802528628 @default.
- W4385841304 cites W2807603420 @default.
- W4385841304 cites W2905107741 @default.
- W4385841304 cites W2905654445 @default.
- W4385841304 cites W2912648593 @default.
- W4385841304 cites W2970466951 @default.
- W4385841304 cites W2973409297 @default.
- W4385841304 cites W2981595408 @default.
- W4385841304 cites W2996376509 @default.
- W4385841304 cites W3032215633 @default.
- W4385841304 cites W3046798806 @default.
- W4385841304 cites W3090386083 @default.
- W4385841304 cites W3093752130 @default.
- W4385841304 cites W3111095108 @default.
- W4385841304 cites W3121804747 @default.
- W4385841304 cites W4200406720 @default.
- W4385841304 cites W4211038654 @default.
- W4385841304 cites W4220965624 @default.
- W4385841304 cites W4229445969 @default.
- W4385841304 cites W4283740261 @default.
- W4385841304 cites W4285097283 @default.
- W4385841304 cites W4313472507 @default.
- W4385841304 cites W4376848385 @default.
- W4385841304 cites W772589830 @default.
- W4385841304 doi "https://doi.org/10.1016/j.xcrm.2023.101133" @default.
- W4385841304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37586317" @default.
- W4385841304 hasPublicationYear "2023" @default.
- W4385841304 type Work @default.
- W4385841304 citedByCount "1" @default.
- W4385841304 countsByYear W43858413042023 @default.
- W4385841304 crossrefType "journal-article" @default.
- W4385841304 hasAuthorship W4385841304A5006311071 @default.
- W4385841304 hasAuthorship W4385841304A5007198288 @default.
- W4385841304 hasAuthorship W4385841304A5021202757 @default.
- W4385841304 hasAuthorship W4385841304A5028159863 @default.
- W4385841304 hasAuthorship W4385841304A5029720669 @default.
- W4385841304 hasAuthorship W4385841304A5030829302 @default.
- W4385841304 hasAuthorship W4385841304A5030976623 @default.
- W4385841304 hasAuthorship W4385841304A5042807080 @default.
- W4385841304 hasAuthorship W4385841304A5049875048 @default.
- W4385841304 hasAuthorship W4385841304A5050096190 @default.
- W4385841304 hasAuthorship W4385841304A5050803462 @default.
- W4385841304 hasAuthorship W4385841304A5055035965 @default.
- W4385841304 hasAuthorship W4385841304A5055618825 @default.
- W4385841304 hasAuthorship W4385841304A5059368310 @default.
- W4385841304 hasAuthorship W4385841304A5064842058 @default.
- W4385841304 hasAuthorship W4385841304A5067835123 @default.
- W4385841304 hasAuthorship W4385841304A5068806771 @default.
- W4385841304 hasAuthorship W4385841304A5076676274 @default.
- W4385841304 hasAuthorship W4385841304A5078634382 @default.
- W4385841304 hasAuthorship W4385841304A5083925626 @default.
- W4385841304 hasAuthorship W4385841304A5088393463 @default.
- W4385841304 hasBestOaLocation W43858413041 @default.